← Front pageReports · Trackers
DRASKER

VACCINE SAFETY & INJURY CLAIMS TRACKER

SIGNAL → INVESTIGATION → ACTION

Regulatory timeline

Federal safety actions on COVID-19 vaccines, in order: signals, pauses, recommendations, warnings, label changes, restrictions and withdrawals — with whether each is still current, was superseded, or was a signal later evaluation did not confirm. A preliminary signal is never shown as an established finding.

  1. FDA; CDC (ACIP)WarningRecognized adverse reactionSuperseded

    Guillain-Barré syndrome warning added for the Janssen vaccine; ACIP reaffirms its use

    Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: Adult recipients

    What changed: Fact sheets revised to describe an observed increased risk of Guillain-Barré syndrome in the 42 days after vaccination.

    FDA revised the Janssen fact sheets to note an observed increased risk of Guillain-Barré syndrome in the 42 days after vaccination; ACIP reviewed the data and concluded benefits outweighed risks.

    Superseded by the 2022 restriction and the 2023 revocation of the Janssen authorization.

    Later: The Janssen authorization was restricted in 2022 and revoked in 2023.

    CDC MMWR (ACIP update, July 2021), via PubMed Central

Thread: janssen gbs

  1. Warning — Guillain-Barré syndrome warning added for the Janssen vaccine; ACIP reaffirms its use Superseded